Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZBH Stock Forecast 2026-2027
$87.56
Current Price
$16.94B
Market Cap
Buy 8
Hold 17
Sell 1
Wall St Analyst Ratings
Distance to ZBH Price Targets
+48.5%
To High Target of $130.00
+7.4%
To Median Target of $94.00
-5.2%
To Low Target of $83.00
ZBH Price Momentum
+0.1%
1 Week Change
-0.7%
1 Month Change
-8.0%
1 Year Change
-2.6%
Year-to-Date Change
-19.1%
From 52W High of $108.29
+10.7%
From 52W Low of $79.12
📊 TOP ANALYST CALLS
Did ZBH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zimmer Biomet is one of their latest high-conviction picks.
Latest ZBH Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ZBH has a neutral consensus with a median price target of $94.00 (ranging from $83.00 to $130.00). The overall analyst rating is Buy (6.9/10). Currently trading at $87.56, the median forecast implies a 7.4% upside. This outlook is supported by 8 Buy, 17 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZBH Analyst Ratings
8
Buy
17
Hold
1
Sell
ZBH Price Target Range
Low
$83.00
Average
$94.00
High
$130.00
Current: $87.56
Latest ZBH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZBH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $110.00 |
| May 28, 2026 | Citigroup | Joanne Wuensch | Neutral | Maintains | $93.00 |
| Apr 29, 2026 | JP Morgan | Neutral | Maintains | $N/A | |
| Apr 29, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Apr 29, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Apr 29, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 29, 2026 | Barclays | Underweight | Maintains | $N/A | |
| Apr 29, 2026 | Truist Securities | Hold | Reiterates | $N/A | |
| Apr 29, 2026 | Stifel | Buy | Maintains | $N/A | |
| Apr 13, 2026 | Leerink Partners | Market Perform | Initiates | $N/A | |
| Mar 23, 2026 | BTIG | Neutral | Downgrade | $N/A | |
| Feb 12, 2026 | Barclays | Underweight | Maintains | $N/A | |
| Feb 11, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 11, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Feb 10, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Feb 10, 2026 | Needham | Hold | Reiterates | $N/A | |
| Jan 28, 2026 | UBS | Sell | Maintains | $N/A | |
| Jan 9, 2026 | Bernstein | Market Perform | Maintains | $N/A | |
| Jan 8, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Jan 5, 2026 | Evercore ISI Group | Outperform | Upgrade | $N/A |
Zimmer Biomet Holdings, Inc. (ZBH) Competitors
The following stocks are similar to Zimmer Biomet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zimmer Biomet Holdings, Inc. (ZBH) Financial Data
Zimmer Biomet Holdings, Inc. has a market capitalization of $16.94B with a P/E ratio of 23.3x. The company generates $8.41B in trailing twelve-month revenue with a 9.1% profit margin.
Revenue growth is +9.3% quarter-over-quarter, while maintaining an operating margin of +19.7% and return on equity of +6.1%.
Valuation Metrics
Market Cap
$16.94B
Enterprise Value
$24.48B
P/E Ratio
23.3x
PEG Ratio
0.7x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
+9.3%
Gross Margin
+72.4%
Operating Margin
+19.7%
Net Margin
+9.1%
EPS Growth
+30.8%
Financial Health
Cash/Price Ratio
+2.8%
Current Ratio
1.7x
Debt/Equity
59.8x
ROE
+6.1%
ROA
+4.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zimmer Biomet Holdings, Inc. (ZBH) Business Model
About Zimmer Biomet Holdings, Inc.
What They Do
Medical devices for musculoskeletal healthcare solutions.
Business Model
The company designs, manufactures, and markets a range of orthopedic reconstructive implants and related products, generating revenue through sales to hospitals, ambulatory surgery centers, and healthcare professionals globally. Its focus on joint replacement and musculoskeletal products ensures a steady demand within the healthcare sector.
Additional Information
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet has a strong presence in the global orthopedic market, particularly in the United States, Europe, and Japan. The company has streamlined its operations by concentrating on large joint reconstruction and related products after spinning off its dental and spine businesses.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
17,000
CEO
Mr. Ivan Tornos
Country
United States
IPO Year
2001
Website
www.zimmerbiomet.comZimmer Biomet Holdings, Inc. (ZBH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
How Big Is the Appendectomy Opportunity for ISRG's Robotic Expansion?
ISRG sees appendectomy as a long-term robotic growth market, but reimbursement limits near-term adoption as clinical evidence continues to build.
Jul 07, 2026
By Indrajit Bandyopadhyay
Analyst Blog
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jul 02, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Zimmer Biomet will hire 500 employees in the next three years for its new technology center in Bengaluru, expanding its operations in India.
Why It Matters
Zimmer Biomet's expansion in India signals growth potential, enhancing operational capabilities and market reach, which could positively impact future revenue and stock performance.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can guide investors in selecting strong stocks that potentially outperform the market for their portfolios.
Why It Matters
Zacks Style Scores can guide investors in selecting stocks with potential for higher returns, influencing portfolio performance and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PCRX will sell its iovera franchise to ZBH for up to $140M, allowing PCRX to concentrate on expanding its biopharmaceutical operations.
Why It Matters
The sale of the iovera franchise for up to $140M indicates PCRX's strategic shift toward biopharmaceuticals, potentially enhancing its growth prospects and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
ISRG shows stronger revenue growth and rising demand for procedures compared to ZBH, alongside expanding AI-driven innovations, indicating better potential upside in 2026.
Why It Matters
ISRG's stronger revenue growth and AI-driven innovation suggest robust future performance, making it a more attractive investment compared to ZBH.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores help investors identify top-rated stocks aligned with their investing styles, providing a useful tool for stock selection.
Why It Matters
Zacks Style Scores can help identify high-potential stocks aligned with specific investment strategies, enhancing portfolio performance and decision-making.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores provide investors a method to identify top-rated stocks according to their investing style, offering a strategic advantage in stock selection.
Why It Matters
The Zacks Style Scores highlight top-rated stocks, aiding investors in making informed decisions and optimizing their portfolios based on specific investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ZBH Stock
What is Zimmer Biomet Holdings, Inc.'s (ZBH) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Zimmer Biomet Holdings, Inc. (ZBH) has a median price target of $94.00. The highest price target is $130.00 and the lowest is $83.00.
Is ZBH stock a good investment in 2027?
According to current analyst ratings, ZBH has 8 Buy ratings, 17 Hold ratings, and 1 Sell ratings. The stock is currently trading at $87.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZBH stock?
Wall Street analysts predict ZBH stock could reach $94.00 in the next 12 months. This represents a 7.4% increase from the current price of $87.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zimmer Biomet Holdings, Inc.'s business model?
The company designs, manufactures, and markets a range of orthopedic reconstructive implants and related products, generating revenue through sales to hospitals, ambulatory surgery centers, and healthcare professionals globally. Its focus on joint replacement and musculoskeletal products ensures a steady demand within the healthcare sector.
What is the highest forecasted price for ZBH Zimmer Biomet Holdings, Inc.?
The highest price target for ZBH is $130.00 from at , which represents a 48.5% increase from the current price of $87.56.
What is the lowest forecasted price for ZBH Zimmer Biomet Holdings, Inc.?
The lowest price target for ZBH is $83.00 from at , which represents a -5.2% decrease from the current price of $87.56.
What is the overall ZBH consensus from analysts for Zimmer Biomet Holdings, Inc.?
The overall analyst consensus for ZBH is neutral. Out of 4 Wall Street analysts, 8 rate it as Buy, 17 as Hold, and 1 as Sell, with a median price target of $94.00.
How accurate are ZBH stock price projections?
Stock price projections, including those for Zimmer Biomet Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 2:29 PM UTC